New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...
A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall ...
Analysis of 2823 adult patients with acute myeloid leukemia (AML) revealed that overall survival decreases almost linearly with increasing age across all European LeukemiaNet (ELN) genetic-risk groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results